ABSTRACT: We describe the synthesis and structure− activity relationship (SAR) studies of divin, a small molecule that blocks bacterial division by perturbing the assembly of proteins at the site of cell septation. The bacteriostatic mechanism of action of divin is distinct from other reported inhibitors of bacterial cell division and provides an opportunity for assessing the therapeutic value of a new class of antimicrobial agents. We demonstrate a convenient synthetic route to divin and its analogues, and describe compounds with a 10-fold increase in solubility and a 4-fold improvement in potency. Divin analogues produce a phenotype that is identical to divin, suggesting that their biological activity comes from a similar mechanism of action. Our studies indicate that the 2-hydroxynaphthalenyl hydrazide portion of divin is essential for its activity and that alterations and substitution to the benzimidazole ring can increase its potency. The SAR study provides a critical opportunity to isolate drug resistant mutants and synthesize photoaffinity probes to determine the cellular target and biomolecular mechanism of divin.
T he development of new antimicrobial agents to combat the emergence of multidrug resistance among clinical pathogens continues to be a challenge. 1 One approach to antimicrobial agent discovery centers upon developing compounds that bind specifically to a cellular target (e.g., DNA gyrase). 2, 3 Another approach that has been gaining traction recently is the identification of compounds that have potent bactericidal or bacteriostatic activity through phenotypic assays/screens, without considering specific cellular targets per se. 4, 5 Membrane-targeting antibiotics represent one class of compounds that have emerged from this approach. 6−8 We recently introduced a new compound, divin (1) , that was discovered using the second track of antibiotic development mentioned above. 9 Divin inhibits late stages of bacterial cell division and produces mother and daughter cells that remain physically fused together and share a common cytoplasm. 9 Peptidoglycan insertion at the septum is blocked in divintreated cells, and the result is a bacteriostatic effect in Gramnegative and Gram-positive bacteria. In our initial studies, the low solubility of 1 in culture media prevented us from isolating, characterizing, and deep sequencing spontaneous mutants that displayed reduced susceptibility to 1. Rather than focusing on the identification of the cellular target, we studied how divin altered the spatial and temporal localization of division proteins at the divisome and found that four late-stage division proteins (i.e., FtsQ, FtsL, FtsW, and FtsB) were mislocalized from the division plane. Unlike the classes of molecules that have been reported to bind FtsZ and inhibit division, 10, 11 divin inhibits assembly of the functional divisome without directly affecting FtsZ. 9 The unique interaction between 1 and the bacterial divisome makes it a useful chemical probe for studying the dynamics of bacterial division; 11 however, its low solubility and modest activity limits its application and prevents the identification of its target.
In this letter, we lay the groundwork for identifying the target of 1 by performing a structure−activity relationship (SAR) study. We demonstrate a convenient synthetic route to divin analogues and describe compounds with improved solubility and potency. Divin analogues with enhanced solubility will enable us to isolate drug resistant mutants and use genomics to identify the drug target. Alternatively, synthesizing a focused library of analogues has guided us in the design of a photoaffinity probe to identify the molecular target of divin using a pull-down approach. 9 These studies lay the groundwork for identifying the molecular target of divin and the development of therapeutic agents for treating clinical infections.
Performing SAR studies required that we develop a flexible synthetic strategy to manipulate elements of 1 while enabling maximum diversification of the structure. We developed a synthetic approach centered upon a sequential, three component coupling of the benzimidazole, the linker, and the 2-hydroxy-1-naphthaldehyde components of divin ( Figure  1) . 12, 13 Each of the three components could be modified independently before they were coupled to produce a range of analogues for characterization and biological testing.
To prepare analogues with variations in the bottom region of the compound, we reacted 2-methyl-1H-benzimidazole 2 with methyl 3-bromopropionate in the presence of anhydrous K 2 CO 3 to prepare ester 3 in 96% yield (Scheme 1). We synthesized the key intermediate 3-(2-methyl-1H-benzimidazol-1-yl) propanohydrazide 4 by hydrazinolysis of 3. Compounds 1 and 5a−j were prepared by the condensation of 4 and corresponding aldehydes with yields ranging from 32% to 93% at a scale of 0.1−0.5 mmol.
It is well-known that N-acylhydrazones may exist as geometrical isomers (E/Z) with respect to the imine bonds and as conformational isomers (cis/trans) around the amide N−C(O) bond. 14, 15 In our study, we obtained a crystal structure of 1·EtOH (Scheme 2), which demonstrated that in the solid state the imine of 1 exists in the E configuration and the N−C(O) existed as trans rotamers (CO anti to the NH). The isomerization of the other analogues in solution depended on their structures. In general, analogues containing a C-2-naphthalenyl or phenyl hydroxyl group (i.e., 5a and 5i) had an isomerization pattern that was similar to 1 and consisted of a mixture of trans C(O)-N and cis C(O)-N isomers in which the trans-isomer was the major product. Analogues lacking a C-2 naphthalenyl or a free hydroxyl group (i.e., 5b-5i) primarily existed as the cis C(O)-N isomer in solution. Analogue 5c (Scheme 2) contained an allyl-protected hydroxyl group. In CDCl 3 /CD 3 OD (95/5%), 5c primarily existed in the cis-isomer (84%) according to 1 H NMR measurements. We removed the allyl protecting group in 5c using Pd(PPh 3 ) 4 /PhSiH 3 and produced 1 in which the trans-isomer was the major product. We selected two linkers, one lacking a methylene group and the other containing an additional methylene group, to explore the relationship between the length of the linker and the activity of analogues (Scheme 3). Specifically, we reacted 2-methyl-1H-benzimidazole (2) with methyl 3-bromoacetate or ethyl 4-bromobutyrate in the presence of K 2 CO 3 to yield the corresponding ester 6a and 6b in 43% and 56% yield, respectively. After hydrazinolysis of 6a and 6b using hydrazine hydrate, we reacted the resulting hydrazides 7a and 7b with 2-hydroxy-1-naphthaldehyde to form the analogues 8a and 8b in 88% and 92% yields, respectively.
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To efficiently prepare divin analogues containing variations in the top region of the molecule, the benzimidazole moiety, we initially attempted to couple the linker to 2-methoxy-1-naphthaldehyde, followed by alkylation of the product with 2-methyl-1H-benzimidazole. This strategy was unsuccessful, and we used the above 3-step sequence to prepare analogues containing variations to the benzimidazole region of 1. We alkylated imidazoles (A-I) with methyl 3-bromopropionate to afford the corresponding esters 9a−h in 40−91% yields (Scheme 4). Hydrazinolysis of 9a−h using hydrazine hydrate provided 10a−h in 59−96% yield. We prepared analogues 11a−j by condensing 10a−h with 2-hydroxy-1-naphthaldehyde.
Compounds 9b, 9c, 10b, and 10c were inseparable mixtures of C-5 and C-6 substituted regioisomers arising from N 1 /N 3 competitive alkylation. 16 From these intermediates, we synthesized analogue 11c as a mixture of regioisomers. Four sets of signals in the 1 H and 13 C NMR spectra indicated that 11c existed as both C-5/C-6 regio-and C(O)−N trans/cis isomers. As expected, the C-5/C-6 dichloro-substituted analogue 11j produced a single regioisomer. The two regiosiomers 11d and 11e that we produced from 10c were separable by flash chromatography. All of the other analogues existed as a mixture of trans C(O)-N and cis C(O)-N rotamers in solution that were similar to 1.
Condensing 4 with 2-acetyloxy-1-naphthaldehyde yielded 1, presumably due to the instability of C-2 phenol ester. To acylate the phenol group of 1, we treated 1 with Ac 2 O in the presence of pyridine at 25°C, which yielded diester 12 in 45% yield (Scheme 5). We also reduced 1 to the corresponding amine 13 in 43% yield. 
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Treating Gram-negative infections can be difficult as the outer membrane reduces the bioavailability of antibiotics. We hence decided to screen analogues of 1 against Gram-negative bacterial strains. We determined the minimum inhibitory concentration (MIC) of each analogue against the model Gram-negative bacteria Caulobacter crescentus CB15N (wild type) and Escherichia coli BW25113 ΔtolC using a CLSI protocol based on serial dilution; 17,18 E. coli BW25113 ΔtolC lacks a central component of one family of efflux drug pumps, and the genetic modification increases the susceptibility of cells to antibiotics. The results are listed in Table 1 .
We found that removing, alkylating, or acylating the phenyl hydroxyl group of divin reduced the activity of analogues (i.e., 5d, 5b, 5c, and 12), thereby indicating the importance of this moiety on the activity of the compound. Changing the position of the phenyl hydroxyl to the C-4 position (i.e., 5e) or replacing the C-4 hydroxyl group with a dimethylamino or fluoro group (i.e., 5f and 5g) dramatically reduced the biological activity. The second aromatic ring of the naphthalenyl moiety was essential for the activity of compounds. Removing the second aromatic ring resulted in inactive analogues (i.e., 5a and 5h). Adding a hydroxyl group to the second ring (i.e., 5i) did not affect the activity.
We found that the imine bond was essential for the activity of 1. Reducing the imine group (i.e., 13) increased the MIC. The hydrogen on the imine group was required for activity, as replacing it with a methyl group (i.e., 5j) produced inactive analogues. We found that the length of the alkyl linker is not important for the activity of 1; analogues with a shorter (8a) or longer linker (8b) had the same MIC as 1 against C. crescentus CB15N. Analogue 8b was slightly more active against E. coli BW25113 ΔtolC than 1, while 8a was ∼2-fold less active than 1.
The benzamidazole ring was the region of divin that was most tolerant to modification; a range of alterations to the benzamidazole group led to small or no changes in the MIC of the corresponding analogues. The methyl group on the benzimidazole ring was not critical to the activity of 1. We found that removing or substituting the methyl group with CF 3 , CH 2 N(Me) 2 , or CH 2 N 3 (i.e., 11f, 11a, 11h, and 11i) did not change the MIC significantly; the only exception was the 3-fold reduction in MIC of the CF 3 analogue 11a against E. coli BW25113 ΔtolC. Analogue 11a had an MIC that was nearly identical to 1 against C. crescentus CB15N. The benzene ring in the benzimidazole group was not essential, as removing it (i.e., 11g) did not change the MIC significantly. Introducing new substituents on the benzene ring improved the MIC of analogue (i.e., 11c, 11e, and 11j) against E. coli BW25113 ΔtolC; the alterations did not change the activity against C. crescentus CB15N. The dichloro analogue 11j had a MIC against E. coli BW25113 ΔtolC that was 2-fold lower than 1.
A key goal of this study was to introduce structural modifications that improved the solubility of 1 without affecting its activity. We determined the solubility of a set of divin analogues in M8 media (with 2% DMSO) using a light scattering assay. 19, 20 M8 is the media we used to study the activity of divin and analogues against E. coli BW25113 ΔtolC cells and a serial of clinic pathogenic strains of bacteria. The results indicated that some modifications led to large improvements in solubility while maintaining the biological activity of the analogues (Table 2) . Compound 8b contained a linker that was longer than 1, and the analogue was 6 times more soluble than 1 in M8 media. Introducing a chloride into the benzimidazole ring (11c) increased the solubility 10-fold compared to 1.
We previously demonstrated that 1 is a bacteriostatic agent by measuring the time-dependent viability of bacterial cells treated with 1.
9 Treating C. crescentus CB15N cells with 1 at its MIC (5 μM) arrested cell division after the initiation of the midcell constriction (Figure 2 ). To evaluate if the most active analogues had the same phenotypic effect as 1 on cells, we imaged C. crescentus CB15N cells treated with divin analogues (at a concentration equivalent to the MIC) after 17 h of incubation ( Figure 2) . All of the compounds produced the same phenotype, which suggests that they share the same mechanism of action as 1. We measured the time-dependent viability of C. crescentus CB15N cells treated with 11c and 11j ( Figure S1 , Supporting Information). The results indicated that analogues 11c and 11j are bacteriostatic, which is similar in mechanism to 1. We also explored the efficacy of 1 and 11j against a panel of clinically relevant strains of bacteria (Table 3) . For these experiments, our choice of 11j versus 8b or 11c was primarily due to its improved activity. Compounds 1 and 11j inhibit the growth of Shigella boydii, Enterobacter aerogenes, Vibrio cholera, and other clinical pathogens. Analogue 11j has a particularly low MIC (3 μM) against V. cholera and a 4-fold increase in potency against E. aerogenes compared to 1.
In this letter, we describe the synthesis of a set of divin analogues and an SAR analysis of these compounds against cells of C. crescentus CB15N and E. coli BW25113 ΔtolC. These studies have enabled us to identify three analogues (8b, 11c, and 11j) with improved solubility and potency. Importantly, these compounds produce the same phenotype as 1, which suggests that they share a similar mechanism of action. Our studies indicate that the 2-hydroxy-1-naphthalenyl portion of 1 is primarily responsible for its activity and that alterations and substitution to the benzimidazole ring can increase its potency. Compounds 11c and 11j were more active than 1 against E. coli BW25113 ΔtolC, and their solubility was 10-and 4-fold higher than 1 in M8 media, respectively. The solubility improvement of these analogues will enable us to pursue the molecular target by isolation and characterization of spontaneous mutants that display reduced susceptibility to the compound. More importantly, the SAR results enabled us to design and synthesize additional analogues that include a reactive azide group and/or a photoactivated diazirine probe, which exhibit virtually identical in vivo activity to 1.
9, 21 We anticipate that these probes will enable us to identify the molecular target of 1, and we plan to report the results of these studies at a later date. 
